about
Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data.Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry.Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials.Long-term outcome after drug eluting stenting in patients with ST-segment elevation myocardial infarction: data from the REAL registry.Different clinical models of CD34 + cells mobilization in patients with cardiovascular disease.In vitro characterization of circulating endothelial progenitor cells isolated from patients with acute coronary syndromeFactor XIIIA-V34L and factor XIIIB-H95R gene variants: effects on survival in myocardial infarction patients.Pro-inflammatory genetic profile and familiarity of acute myocardial infarctionMechanisms of remodelling: a question of life (stem cell production) and death (myocyte apoptosis).Genetic determinants of on-clopidogrel high platelet reactivity.Thrombin generation assay: a new tool to predict and optimize clinical outcome in cardiovascular patients?Coagulation factors and recurrence of ischemic and bleeding adverse events in patients with acute coronary syndromes.Molecular identity of the mitochondrial permeability transition pore and its role in ischemia-reperfusion injury.Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management.Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis.Antiplatelet Treatment Reduces All-Cause Mortality in COPD Patients: A Systematic Review and Meta-Analysis.Meta-Analysis of the Duration of Dual Antiplatelet Therapy in Patients Treated With Second-Generation Drug-Eluting Stents.Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.Impact of Culprit Plaque and Atherothrombotic Components on Incomplete Stent Apposition in Patients With ST-Elevation Myocardial Infarction Treated With Everolimus-Eluting Stents - An OCTAVIA Substudy.Bioresorbable Scaffold vs. Second Generation Drug Eluting Stent in Long Coronary Lesions requiring Overlap: A Propensity-Matched Comparison (the UNDERDOGS study).Fractional Flow Reserve Evaluation and Chronic Kidney Disease: Analysis From a Multicenter Italian Registry (the FREAK Study).Risk of Adverse Cardiac and Bleeding Events Following Cardiac and Noncardiac Surgery in Patients With Coronary Stent: How Important Is the Interplay Between Stent Type and Time From Stenting to Surgery?Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial.Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial.Relationship between Troponin Elevation, Cardiovascular History and Adverse Events in Patients with acute exacerbation of COPD.Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treaLong-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrThe 5-year clinical outcomes after a randomized comparison of sirolimus-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction.Antithrombotic management and 1-year outcome of patients on oral anticoagulation undergoing coronary stent implantation (from the Registro Regionale Angioplastiche Emilia-Romagna Registry).Coronary artery surgery versus percutaneous coronary intervention in octogenarians: long-term results.Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in PatienPersistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus TirofibanSex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: insights from the Multicenter Evaluation of Single High-Dose Bolus TiroImpact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention.Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia).Relevance of gender in patients with acute myocardial infarction undergoing coronary interventions.Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY).Incidence and outcome of high on-treatment platelet reactivity in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] study).
P50
Q31028203-9BB3CBC8-6554-4AEC-B209-1D3D9E4DB0E2Q31070055-6E0334D4-2CC6-4C4C-9BC5-7FF13DE3C459Q33386229-B2E4FD75-38C7-4F64-B54E-162FFFA26F48Q33389674-24CFB70A-D8DE-4F97-9161-E3298CB152DCQ33783495-8F70D1F5-0B27-4A50-AA35-9925320CD59FQ34586902-21E7DB33-8A04-4F30-8BAA-4112CF647A3BQ35795759-9AF57307-F304-48CC-843B-5ECB22B0E15EQ36127718-0DF225CA-6A17-4901-9BA3-C98AB1569A9AQ37613359-DF95E188-0570-4573-92F2-EE2F08D67944Q37882695-54D050EE-28F3-4D59-99FD-453334E1405EQ38017911-75BDA65E-AFC1-4B84-8904-40F3CF937BA7Q38119341-619C8D35-6EA7-47AD-87A4-57AF45C9358AQ38244750-5EC201F2-53A9-4CD0-B95D-769E95119996Q38244750-A140E041-DFB0-41A5-A388-7C707B2E8B01Q38342003-E83B15A6-A007-4125-84DD-97A4D18290E5Q38474249-FB36756D-AF6F-4B34-B9CB-F354B98647B1Q38475263-FF71A357-B570-40C8-B09F-707D670BF94AQ38672259-B001FD17-3FE7-41EF-9027-B9231D809AD8Q38822612-85ECA875-6073-463B-96B3-05BA1284DB76Q39904581-A1E74BE1-BD18-49AA-B030-532E03DCA980Q40016322-CE7BA9BA-7F80-4FAB-B3F0-D72F6390DC7CQ40040965-C50E8096-509D-4034-B636-12F4BE8014EAQ40158189-F5D8D14B-454C-41DC-9862-FAC3E8E296B9Q40232413-35D09832-3CCC-4538-88D3-2493F6E33C61Q40371663-7C42072A-5860-4ACB-90CB-702DBA956E48Q40860141-7C0446DE-9DE9-448E-B4DF-64F4F3F774D8Q41211392-2CA60017-3007-4637-B6D2-7637E0AB89B3Q41346350-D97487B5-5F44-404E-B8A8-E565612C54BCQ42795434-C69F5C7B-9A16-4AF0-BF05-F861F8A91A7FQ42857052-93BBBE63-43BE-4E53-9959-75F5318F3BCFQ43247826-BD6079CE-5D85-4EC1-9799-654528EBDCDAQ43971068-AACF0C11-8398-42B6-9FBB-296F59A29D3AQ44355150-8523FA5F-7038-4023-BADC-A65BE04626AAQ44475877-DEAB994F-44C2-41B5-ADA0-91A46A293627Q44820991-DCD3B259-99EB-4501-B7E5-A0E0DECDD2E1Q44961041-D38BC8DC-5DB9-4200-B8D3-8C8F1461FFB6Q45013687-A1C0636F-F94C-479A-B84C-4116F4E985E8Q45139787-6A85EBB3-74E1-48B9-A663-4D8F4C0CD259Q45219785-09AD48EE-D4FA-4703-9A37-4FEB5FC27877Q45592477-B0940DCC-79F7-4A47-867E-ACF3B1F9EEE6
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Gianluca Campo
@ast
Gianluca Campo
@en
Gianluca Campo
@es
Gianluca Campo
@sl
type
label
Gianluca Campo
@ast
Gianluca Campo
@en
Gianluca Campo
@es
Gianluca Campo
@sl
prefLabel
Gianluca Campo
@ast
Gianluca Campo
@en
Gianluca Campo
@es
Gianluca Campo
@sl
P106
P1153
8937083300
P21
P31
P496
0000-0002-5150-188X